Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?

Novo M, Nowakowski GS, Habermann TM, Witzig TE, Micallef IN, Johnston PB, Inwards DJ, Botto B, Ristow KM, Young JR, Vitolo U, Ansell SM.

Leuk Lymphoma. 2019 Sep 26:1-10. doi: 10.1080/10428194.2019.1663422. [Epub ahead of print]

PMID:
31556355
2.

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2019 Sep 20. pii: mdz386. doi: 10.1093/annonc/mdz386. [Epub ahead of print] No abstract available.

PMID:
31539020
3.

Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.

Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U.

Expert Rev Hematol. 2019 Sep;12(9):787-796. doi: 10.1080/17474086.2019.1643232. Epub 2019 Aug 8.

PMID:
31305170
4.

Variable global distribution of cell-of-origin from the ROBUST phase 3 study in diffuse large B-cell lymphoma.

Nowakowski GS, Chiappella A, Witzig TE, Scott DW, Spina M, Gascoyne RD, Zhang L, Russo J, Kang J, Zhang J, Xu Y, Vitolo U.

Haematologica. 2019 Jun 20. pii: haematol.2019.220475. doi: 10.3324/haematol.2019.220475. [Epub ahead of print]

5.

High-grade B-cell lymphoma: how to diagnose and treat.

Novo M, Castellino A, Nicolosi M, Santambrogio E, Vassallo F, Chiappella A, Vitolo U.

Expert Rev Hematol. 2019 Jul;12(7):497-506. doi: 10.1080/17474086.2019.1624157. Epub 2019 Jun 19.

PMID:
31150587
6.

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.

Klanova M, Oestergaard MZ, Trněný M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G.

Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.

PMID:
31053601
7.

Monoclonal antibody-drug conjugates in B-cell lymphomas.

Chiappella A, Vitolo U.

Lancet Haematol. 2019 May;6(5):e232-e233. doi: 10.1016/S2352-3026(19)30048-1. Epub 2019 Mar 29. No abstract available.

PMID:
30935954
8.

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.

Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M.

Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7.

9.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

10.

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.

Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network.

Br J Haematol. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8. No abstract available.

PMID:
30407625
11.

Histological transformation and secondary malignancies in follicular lymphoma.

Vitolo U, Chiappella A.

Lancet Haematol. 2018 Nov;5(11):e496-e497. doi: 10.1016/S2352-3026(18)30170-4. No abstract available.

PMID:
30389030
12.

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2018 Dec 1;29(12):2363-2370. doi: 10.1093/annonc/mdy450.

13.

Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma.

Vitolo U, Chiappella A.

Lancet Oncol. 2018 Sep;19(9):1144-1146. doi: 10.1016/S1470-2045(18)30510-2. Epub 2018 Aug 16. No abstract available.

PMID:
30122617
14.

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.

Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.

PMID:
30010187
15.

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

Ayed AO, Chiappella A, Pederson L, Laplant BR, Congiu AG, Gaidano G, Spina M, Re A, Cavallo F, Musuraca G, Macon WR, Witzig T, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Jun 26;8(7):63. doi: 10.1038/s41408-018-0097-0.

16.

Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma.

Derenzini E, Agostinelli C, Rossi A, Rossi M, Scellato F, Melle F, Motta G, Fabbri M, Diop F, Kodipad AA, Chiappella A, Vitolo U, Gaidano G, Tarella C, Pileri S.

Br J Haematol. 2019 Apr;185(2):330-334. doi: 10.1111/bjh.15442. Epub 2018 Jun 17. No abstract available.

17.

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G.

J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.

PMID:
29851546
18.

Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.

Carella AM, Corradini P, Mussetti A, Ricardi U, Vitolo U, Viviani S.

Ann Hematol. 2018 Aug;97(8):1301-1315. doi: 10.1007/s00277-018-3366-x. Epub 2018 May 25. Review.

PMID:
29802458
19.

Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.

Ciochetto C, Botto B, Passera R, Bellò M, Benevolo G, Boccomini C, Castellino A, Chiappella A, Freilone R, Nicolosi M, Orsucci L, Pecoraro C, Pregno P, Bisi G, Vitolo U.

Ann Hematol. 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16.

PMID:
29663029
20.

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. [Epub ahead of print]

PMID:
29624703
21.

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.

Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, Mann KK, Morin R, Alcaide M, Bushell K, Fanin R, Levis A.

Leuk Lymphoma. 2018 Dec;59(12):2904-2910. doi: 10.1080/10428194.2018.1452208. Epub 2018 Apr 4.

PMID:
29616865
22.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7. Review.

PMID:
29512173
23.

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V.

Haematologica. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22.

24.

Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.

Vitolo U, Chiappella A.

Lancet Oncol. 2018 Feb;19(2):162-163. doi: 10.1016/S1470-2045(17)30913-0. Epub 2017 Dec 21. No abstract available.

PMID:
29276023
25.

A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.

Ghione P, Cavallo F, Visco C, Chen Z, Castellino A, Tisi MC, Dogliotti I, Nicolosi M, Boccadoro M, Leonard JP, Vitolo U, Martin P.

Br J Haematol. 2018 Dec;183(5):828-831. doi: 10.1111/bjh.15057. Epub 2017 Dec 19. No abstract available.

26.

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M.

Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

27.

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M.

J Clin Oncol. 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652. Epub 2017 Nov 2.

PMID:
29095677
28.

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply.

Chiappella A, Martelli M, Evangelista A, Vitolo U.

Lancet Oncol. 2017 Oct;18(10):e558. doi: 10.1016/S1470-2045(17)30702-7. No abstract available.

PMID:
28971817
29.

Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.

Frairia C, Aydin S, Audisio E, Riera L, Aliberti S, Allione B, Busca A, D'Ardia S, Dellacasa CM, Demurtas A, Evangelista A, Ciccone G, Francia di Celle P, Nicolino B, Stacchini A, Marmont F, Vitolo U.

Leuk Res. 2017 Oct;61:10-17. doi: 10.1016/j.leukres.2017.08.008. Epub 2017 Aug 30.

PMID:
28846953
30.

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH.

J Clin Oncol. 2017 Nov 1;35(31):3529-3537. doi: 10.1200/JCO.2017.73.3402. Epub 2017 Aug 10.

PMID:
28796588
31.

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.

Cascione L, Rinaldi A, Chiappella A, Kwee I, Ciccone G, Altenbuchinger M, Kohler C, Vitolo U, Inghirami G, Bertoni F.

Br J Haematol. 2018 Aug;182(3):453-456. doi: 10.1111/bjh.14817. Epub 2017 Jul 24. No abstract available.

PMID:
28737236
32.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.

Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

PMID:
28668386
33.

Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.

Chiappella A, Santambrogio E, Castellino A, Nicolosi M, Vitolo U.

Expert Rev Hematol. 2017 Aug;10(8):697-705. doi: 10.1080/17474086.2017.1350164. Epub 2017 Jul 14. Review.

PMID:
28665232
34.

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL.

Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289.

35.

Current options to manage Waldenström's macroglobulinemia.

Benevolo G, Nicolosi M, Santambrogio E, Vitolo U.

Expert Rev Hematol. 2017 Jul;10(7):637-647. doi: 10.1080/17474086.2017.1339596. Epub 2017 Jun 19. Review.

PMID:
28592170
36.

Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.

Giaccone L, Festuccia M, Zallio F, Sorasio R, Brunello L, Maffini E, Dellacasa C, Passera R, Iovino G, Aydin S, Boccadoro M, Vitolo U, Mordini N, Pini M, Busca A, Bruno B.

Bone Marrow Transplant. 2017 Aug;52(8):1208-1211. doi: 10.1038/bmt.2017.99. Epub 2017 Jun 5. No abstract available.

PMID:
28581461
37.

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).

Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F, Monaco F, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Visco C, Calabrese M, Limberti G, Levis A, Contino L, Ciccone G, Ladetto M.

Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895. [Epub ahead of print]

PMID:
28447710
38.

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C.

J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29. Erratum in: J Clin Oncol. 2017 Jul 10;35(20):2342.

PMID:
28355112
39.

Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.

Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, van Oers MH, Fortpied C, Ghielmini M, Pettengell R, Witzens-Harig M, Dreger P, Vitolo U, Gomes da Silva M, Evangelista A, Li H, Freedman L, Habermann TM, Shpilberg O.

Eur J Cancer. 2017 May;76:216-225. doi: 10.1016/j.ejca.2017.01.021. Epub 2017 Mar 21.

PMID:
28336303
40.

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2017 Dec 1;28(12):3109. doi: 10.1093/annonc/mdx020. No abstract available.

PMID:
28327933
41.

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

Chiappella A, Castellino A, Nicolosi M, Santambrogio E, Vitolo U.

Expert Rev Hematol. 2017 Apr;10(4):289-297. doi: 10.1080/17474086.2017.1305264. Epub 2017 Mar 27. Review.

PMID:
28290728
42.

Recent advances in clinical studies and the evolving role of subtyping for patients with diffuse large B-cell lymphoma.

Nowakowski GS, Vitolo U.

Future Oncol. 2017 Apr;13(10):859-862. doi: 10.2217/fon-2016-0567. Epub 2017 Feb 10. No abstract available.

43.

Follicular Lymphoma: The Management of Elderly Patient.

Castellino A, Santambrogio E, Nicolosi M, Botto B, Boccomini C, Vitolo U.

Mediterr J Hematol Infect Dis. 2017 Jan 1;9(1):e2017009. doi: 10.4084/MJHID.2017.009. eCollection 2017. Review.

44.

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ.

J Clin Oncol. 2017 Feb 10;35(5):552-560. doi: 10.1200/JCO.2016.70.8651. Epub 2016 Dec 28.

PMID:
28029309
45.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U.

Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.

PMID:
27927586
46.

State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.

Chiappella A, Castellino A, Vitolo U.

Hematol Oncol Clin North Am. 2016 Dec;30(6):1147-1162. doi: 10.1016/j.hoc.2016.07.002. Review.

PMID:
27888872
47.
48.

Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.

Levis M, Piva C, Filippi AR, Botto B, Gavarotti P, Pregno P, Nicolosi M, Freilone R, Parvis G, Gottardi D, Vitolo U, Ricardi U.

Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):14-22. doi: 10.1016/j.clml.2016.09.008. Epub 2016 Sep 17.

PMID:
27727134
49.

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F.

Am J Hematol. 2017 Jan;92(1):37-41. doi: 10.1002/ajh.24572. Epub 2016 Nov 12.

50.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA.

Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

PMID:
27692305

Supplemental Content

Loading ...
Support Center